APP Pharmaceuticals Announces Increased Availability of APP Diprivan(R) and APP Propofol 1%

APP Pharmaceuticals Announces Increased Availability of APP Diprivan(R) and APP Propofol 1%

SCHAUMBURG, Ill., Oct 14, 2011 (BUSINESS WIRE) -- APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today increased availability of APP Diprivan(R) (propofol 1%) and APP Propofol 1% (authorized generic Diprivan(R)). Both are now readily available and APP has the supply necessary to meet the clinical needs of health care professionals.

"As the leading supplier of Diprivan and Propofol, APP Pharmaceuticals recognizes the vital clinical importance of maintaining a consistent supply of this important drug and has responded quickly in the face of drug shortages to meet market demand," said John Ducker, President and Chief Executive Officer of APP Pharmaceuticals. "To accomplish this goal, APP significantly increased production in order to supply the U.S. market."

Added Scott Meacham, Executive Vice President and Chief Commercial Officer, "Responsiveness is our commitment to clinicians and APP Pharmaceuticals has worked hard to ensure that a sufficient and ample supply is available."

To keep clinicians informed on a real-time basis of critical drug shortages, APP previously established the APP Drug Shortage Helpline to assist health care professionals with critical drug needs.

About Diprivan(R) (propofol 1%) and APP Propofol 1% (authorized generic Diprivan(R))

Propofol is a fast-onset, short-acting sedative-hypnotic agent that is used for the induction and maintenance of anesthesia or sedation. The drug is marketed under the brand name, Diprivan(R), and is also available as a generic drug, APP Propofol 1%. APP is the only company that includes EDTA, an anti-microbial growth retardant in the formulation of its product.

About APP Pharmaceuticals, Inc.

APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on September 10, 2008. For more information about APP Pharmaceuticals, Inc., please visit the company's Web site at www.APPpharma.com .

About Fresenius Kabi AG

Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi's core product range includes infusion solutions, blood volume substitutes, I.V. drugs and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With the philosophy "caring for life" and a comprehensive product portfolio, the company aims at improving the quality of life of critically and chronically ill patients all over the world. In 2010, Fresenius Kabi achieved sales of EUR 3,672 million and an operating profit of EUR 737 million. For more information visit the company's Web site at www.fresenius-kabi.com . Fresenius Kabi AG is a 100% subsidiary of Fresenius SE & Co. KGaA.

Forward-Looking Statement

The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our products. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2010 and other documents the company has filed with the Securities and Exchange Commission.

The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company's expectations.

Diprivan(R) is a registered trademark of APP Pharmaceuticals.

SOURCE: APP Pharmaceuticals, Inc.



APP Contact:
Debra Lynn Ross, ABC
Director, Corporate Communications
APP Pharmaceuticals, Inc.
(847) 969-8026
[email protected]

 

 

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.